A detailed history of Great Point Partners LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Great Point Partners LLC holds 750,000 shares of VRDN stock, worth $14.8 Million. This represents 7.89% of its overall portfolio holdings.

Number of Shares
750,000
Previous 500,000 50.0%
Holding current value
$14.8 Million
Previous $6.51 Million 162.29%
% of portfolio
7.89%
Previous 1.72%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$12.16 - $23.33 $3.04 Million - $5.83 Million
250,000 Added 50.0%
750,000 $17.1 Million
Q2 2024

Aug 14, 2024

SELL
$11.6 - $17.26 $9.69 Million - $14.4 Million
-835,000 Reduced 62.55%
500,000 $6.51 Million
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $22.8 Million - $31.8 Million
1,335,000 New
1,335,000 $23.4 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $785M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.